Key result
Thrombopoietin synergizes with other agonists to potentiate the protein-kinase-C-mediated activation of the ERK pathway in human platelets.
Why the study?
Does thrombopoietin potentiate the ERK activation pathway in human platelets?
Does thrombopoietin potentiate the ERK activation pathway in human platelets?
Thrombopoietin synergizes with other agonists to potentiate the ERK activation pathway in human platelets, which may regulate cytoskeletal functions rather than primary aggregation.
Answers are grounded in this paper and cite their sources.
May modulate cytoskeletal over aggregatory platelet responses; leaves open clinical relevance in humans.
The thrombopoietin (TPO) receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. We investigated the effect of TPO on the extracellular signal-regulated kinase (ERK) activation pathway in human platelets. TPO by itself did not activate ERK1, ERK2 and protein kinase C (PKC), whereas TPO directly enhanced the PKC-dependent activation of ERKs induced by other agonists including thrombin and phorbol esters, without affecting the PKC activation by those agonists. TPO did not activate the mitogen-activated protein kinase/ERK kinases, MEK1 and MEK2, but activated Raf-1 and directly augmented the PKC-mediated MEK activation, suggesting that TPO primarily potentiates the ERK pathway through regulating MEKs or upstream steps of MEKs including Raf-1. The MEK inhibitor PD098059 failed to affect not only thrombin-induced or phorbol ester-induced aggregation, but also potentiation of aggregation by TPO, denying the primary involvement of ERKs and MEKs in those events. ERKs and MEKs were located mainly in the detergent-soluble/non-cytoskeletal fractions. ERKs but not MEKs were relocated to the cytoskeleton following platelet aggregation and actin polymerization. These data indicate that TPO synergizes with other agonists in the ERK activation pathway of platelets and that this synergy might affect functions of the cytoskeleton possibly regulated by ERKs.
No takes yet. Share an insight, caveat, or question.
Ezumi et al. (1998) studied this question. Thrombopoietin (TPO) was evaluated on ERK activation pathway. Thrombopoietin synergizes with other agonists to potentiate the protein-kinase-C-mediated activation of the ERK pathway in human platelets.
Synapse has enriched 10 related papers. Consider them for comparative context: